The role of the thymus in the maintenance of natural killer cells in vivo

Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration

The effects of different in vivo thymosin alpha one (T alpha 1) treatments on T-cell responses inhibited by cocaine abuse were studied. Administration during cocaine treatment promoted a faster recovery of normal natural killer (NK) cell activity after the suspension of abuse. Suspension of cocaine plus repeated T alpha 1 administrations strongly restored NK activity and, interestingly, spleen cells from mice treated with T alpha 1 during and after cocaine administration achieved a very rapid recovery and the greatest stimulation of natural cytotoxicity. This last treatment also restored the cocaine-inhibited specific T-cell response (i.e. allogeneic cytotoxic T-lymphocyte (CTL) generation) and abrogated the cocaine-induced suppression of interferon gamma (IFN-gamma), interleukin 2 (IL-2) and IL-4 production. Finally restoration and induction of thymic cellularity were significant when T alpha 1 was given during and after cocaine administration. The present investigation provides evidence for the first time that thymic hormones could be of potential value in controlling cocaine-induced impairment of T-cell-mediated immunity in the mouse.

In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes

Natural killer (NK) cells are thought to play a role in host defence against malignancy and infection, in immunoregulation and as precursor cells in a generation of lymphokine-activated killer (LAK) cells which can lyse NK-resistant tumour cells. As the lung is a major site for malignancy and infection and as there are large numbers of lymphoid cells including NK cells in the interstitial compartment of the lung, we evaluated the capacity of interleukin-2 (IL-2), a lymphokine capable of augmenting NK activity in vitro, to augment lung NK cell activity in vivo, using different routes of IL-2 administration. We compared both systemic (i.v. and i.p.) and local (intrapleural and inhalation) routes of IL-2 administration (50,000 U/daily for 5 days) using CBA mice, assessing NK and LAK cell activity in the spleen (systemic) and in the lung. The target cells used for these studies were the YAC-1 (NK-sensitive) and P815, NO36 and HA56 (NK-resistant, LAK-sensitive) cell lines. Splenic NK activity was increased by 1.4-1.9-fold for i.v./i.p., respectively, compared with controls with both systemic routes of administration, and lung NK activity was increased 3.2-fold and 3.8-fold (i.v./i.p, respectively, P less than 0.05), to levels which were comparable to systemic (splenic) NK activity following the same therapy. Intrapleural IL-2 administration similarly enhanced lung NK activity (3.3-fold) and splenic NK activity (1.3-fold; P less than 0.05 versus controls for both). Surprisingly, inhaled IL-2 suppressed both splenic and lung NK cell activity (84 +/- 8% and 78 +/- 10% suppression, respectively, P less than 0.05). LAK cell activity was also enhanced in the lung by 1.8-8-fold in response to i.v., i.p. and intrapleural IL-2, whereas inhaled IL-2 was ineffective in generating LAK cell activity. These results suggest that the systemic and intrapleural administration of IL-2 effectively boost pulmonary NK and LAK activity whereas inhalation of IL-2 does not. Thus, in clinical situations where boosting of local lung NK or LAK cell activity is desired, these routes of IL-2 administration may be effective.

Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice

We have investigated the possibility of thymosin alpha 1 (TH) cooperating with alpha beta-interferon (IFN) in boosting natural killer (NK) activity in tumor-bearing, immunosuppressed mice in vivo. Treatment with a single injection of 30,000 IU of IFN 24 h before testing enhanced NK activity in tumor-bearing mice if the IFN was administered 9 days after tumor inoculation, when the animals have normal NK responsiveness. On the other hand, the same treatment led to lower or no improvement of NK responses if the treatment was given 13 or 17 days after tumor inoculation, at a time when tumor growth causes immunosuppression. However, combination treatment with TH (200 micrograms/kg) for 4 days, followed by IFN was found to restore normal NK cell activity. Selective depletion of antigen-positive cells showed that killer cells stimulated by combination treatment with TH and IFN seem to bear phenotypic characteristics of NK cells. These studies provide the first documentation of a novel combination approach to reconstitution of immunosuppressed tumor-bearing mice using TH and IFN. We hypothesize that TH restores NK boosting activity by IFN by effecting the differentiation/induction of precursor populations of IFN-responsive cells.

Influence of thymic hormone on cell-mediated and humoral immune responses in Marek's disease

A reduction in the secretion of thymic hormones, and in particular thymulin, can be demonstrated in chickens following the thymic atrophy induced by Marek's disease virus (MDV) infection. In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors. No effect was noted on the levels of neutralizing anti-viral antibodies. Nevertheless, thymulin treatment resulted in significant suppression of the cellular immune response 4-6 weeks post-inoculation, monitored by splenic cytotoxicity against MD-specific and natural killer-sensitive lymphoblastoid cell lines.

Immunologic effects of perinatal exposure of rats to dioctyltin dichloride

Studies were conducted to determine the period of immune system development that was most sensitive to perturbation by the known immunotoxicant di-n-octyltin dichloride (DOTC). Fischer 344 rats were exposed prenatally, both pre- and postnatally, or postnatally to DOTC by oral gavage of pregnant and/or lactating females. At various ages, ranging from 3 to 16 wk of age, offspring were examined for a number of immune functions. These included body and lymphoid organ weights; lymphoproliferative responses to B- and T-cell mitogens; natural killer cell activity; and primary antibody response to sheep erythrocytes. Prenatal (10-20 of gestation), pre- and postnatal (d 11-20 of gestation and 2-11 d of age), or postnatal (2-13 d of age) oral dosing of dams with 20-50 mg/kg DOTC resulted in no consistent alteration in immune function in offspring. However, direct oral dosing of rat pups to 5-15 mg/kg DOTC, beginning at 3 d of age and then 3 times per week up to 24 d of age for a total of 10 doses, resulted in significant suppression of the lymphoproliferative response of splenocytes to a T-cell mitogen in 10-wk-old rats (i.e., 7 wk after the last exposure to DOTC). Lymphoproliferative responses returned to control levels by 12 wk of age. In comparison young adult (8 wk old) rats dosed with 10 or 20 mg/kg DOTC under an identical dosing schedule (i.e., 3 times per week for a total of 10 doses) showed no suppression in the mitogen response of splenocytes 4 wk after the last exposure to DOTC. These results suggest that direct dosing of pups during early postnatal life may be the most effective means of inducing immunosuppression with DOTC during immune system development. The results also provide evidence for the greater sensitivity of the developing immune system compared with the fully developed immune system for a known immunotoxicant.

Modulation of natural killer activity by thymosin alpha 1 and interferon

A single injection of alpha beta-interferon (alpha beta-IFN) (30000 units/mouse), a major biological modifier of natural killer (NK) cytolytic activity, strongly stimulated NK activity in normal mice, as expected, while the same treatment did not statistically alter the NK response in cyclophosphamide (CY)-suppressed animals. We investigated the possibility of thymosin alpha 1 cooperating with alpha beta-IFN in boosting NK activity in CY-suppressed animals. The results show that treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of alpha beta-IFN 24 h before testing, strongly restored NK activity in CY-suppressed mice. Thymosin alpha 1 was, moreover, able to accelerate the recovery rate of NK activity in bone marrow reconstituted murine chimeras. Taken together the data support the concept that the synergic effect between thymosin alpha 1 and alpha beta-IFN could be the result of effects on differentiation of the NK lineage at different levels.